A World Health Organization (WHO) advisory group recommended evaluation of Moderna’s Ebola vaccine candidate in the Democratic Republic of the Congo as the company’s shares rose 13.1% Wednesday before third-quarter results due Nov. 6.
The shares finished Wednesday at $258.38, after reaching an intraday high of $258.72. Wednesday’s high was 1.67% above the Oct. 21 intraday peak of $254.48, and the close was 5.11% higher than the $245.81 finish that day.
The WHO’s Technical Advisory Group on Candidate Vaccine Prioritization recommended evaluating Moderna’s Ebola vaccine candidate mRNA-1469 in Tumaini, an ongoing Phase 2/3 Ebola study in the Democratic Republic of the Congo.
Moderna’s third-quarter results are due Friday, Nov. 6, and the company has set a conference call for 8 a.m. ET.
The annual gathering of the American Society of Hematology is slated to feature an oral session with initial clinical findings on mRNA-2808, Moderna’s experimental multiple myeloma treatment.
